| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.5 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.036 | 0.5 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |